Background: This study evaluated the efficiency of corticosteroid, leflunomide and mesenchymal stem cells (MSCs) in the treatment of pediatric idiopathic pulmonary hemosiderosis (IPH). Methods: Ten patients were included in the study. The diagnosis of IPH was based on clinical symptoms, laboratory examinations and pulmonary hemosiderosis. Induction therapy consisted of methylprednisolone pulse therapy, followed by prednisone plus leflunomide. Maintenance therapy consisted of low-dose prednisone, leflunomide and administration of MSCs. Results: All the patients achieved complete response after treatment with corticosteroid, leflunomide and MSCs. The median follow-up was 23 months (range: 4-34 months). Moreover, administration of MSCs induced an increase in the percentage of CD4 þ CD25 þ regulatory T cells but a decrease in the percentage of Th17 cells. Conclusion: Treatment with corticosteroid, leflunomide and MSCs for pediatric IPH was safe and effective.
I N T R O D U C T I O N
Idiopathic pulmonary hemosiderosis (IPH) is a rare and life-threatening condition that causes recurrent episodes of diffuse alveolar hemorrhage. It is characterized by hemoptysis, dyspnea, alveolar opacities on chest radiographs and iron-deficiency anemia. The estimated incidence of IPH in children is 0.24-1.23 cases per million, and IPH is associated with a high mortality rate [1] [2] [3] . The etiology of IPH may include allergic, environmental, genetic and autoimmune factors. In fact, the frequent association of autoimmune disorders with IPH indicates the presence of an underlying immune disorder [4, 5] . Systemic corticosteroids are the mainstay of therapy for IPH. However, some patients continue to experience recurring episodes of alveolar hemorrhage despite treatment with a full course of corticosteroids or during tapering of oral corticosteroids. An immunosuppressive agent is required to treat these patients. Nevertheless, there is still controversy and a lack of clear evidence regarding the management of such patients [6] [7] [8] . Thus, it is important to explore a new therapeutic strategy for the treatment of IPH.
Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties. These cells can repair tissue after injury and downregulate many of the effector functions of immune cells that participate in the autoimmune response, converting them into regulatory cells [9, 10] . In the present study, 10 pediatric patients with IPH were treated with corticosteroid, leflunomide and MSCs to evaluate the efficacy of this combination therapy for pediatric IPH.
M E T H O D S
We conducted a retrospective analysis of pediatric patients with IPH at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, between January 2013 and June 2016. The study was conducted after approval from the ethics committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Written informed consent was obtained from all of the patients' parents or guardians. The diagnosis of IPH was based on clinical symptoms, laboratory examinations and the presence of pulmonary hemosiderosis (shown by infiltrates on chest radiographs and the presence of hemosiderin-laden macrophages in sputum, gastric lavage fluid or bronchoalveolar lavage fluid). Routine blood and urine tests, blood biochemistry tests and autoimmune antibodies tests were performed for all the patients. The autoimmune antibodies included cytoplasmic anti-neutrophil cytoplasmic antibody (c-ANCA), perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA), antidouble-strand DNA (ds-DNA) antibody, anti-nuclear antibody (ANA), rheumatoid factor (RF) and anti-glomerular basement membrane (anti-GBM) antibody. Moreover, lymphocyte subpopulations, including CD4 þ CD25 þ T cells and Th17 cells, were analyzed using a flow cytometer.
All the patients with IPH received induction therapy and maintenance therapy. Induction therapy consisted of methylprednisolone pulse therapy (10 mg/kg/day, 3 days), followed by prednisone (2 mg/kg/day, tapered gradually at 8 weeks) plus leflunomide (0.3-0.5 mg/kg/day). The subsequent maintenance therapy consisted of low-dose corticosteroid (prednisone: 5 mg/day, 12 months), leflunomide (0.3-0.5 mg/kg/day, 12 months) and MSC administration (on the first day of maintenance therapy). Briefly, bone marrow-derived MSCs were aspirated from human leukocyte antigen (HLA)-matched donors or HLA-disparate third-party adult donors. Human MSCs were isolated and cultured in vitro as previously described [11, 12] . MSCs from the third passage were harvested and administered to the patients by intravenous infusion over 30 min. The MSC dose scheme was 1.0 Â10 6 /kg body weight. Peripheral blood samples were obtained from the patients for flow cytometric analysis 1 day before MSC administration and 10 days after MSC administration.
After the treatments, all patients were followed up in our outpatient department. Patients' clinical features, routine blood tests, blood biochemistry tests and chest radiographs were monitored. Complete response was defined as hemoglobin >120 g/l without reticulocytosis, normal serum iron and no evidence of pulmonary hemorrhage, including hemoptysis and new pulmonary infiltrates on chest radiographs. Flow cytometry data were compared using a twosided paired-samples t test; p <0.05 was considered statistically significant. Analysis was performed with the SPSS software package (version 20.0).
R E S U L T S
Ten pediatric patients with IPH were recruited in our study. As shown in Table 1 , there were three male and seven female patients, with a median age of 4.5 years (range: 2-10 years) at the time of disease onset and a median disease course of 11 months (range: 4-36 months). The common clinical symptoms were cough, breathlessness, hemoptysis and anemia in all patients. The laboratory examinations showed reticulocytosis, anemia, microcytosis and low levels of serum iron. The median hemoglobin at diagnosis was 48.5 g/l (range: 27-76 g/l). The results of work-ups for c-ANCA, p-ANCA, anti-ds-DNA antibody, ANA, RF and anti-GBM antibody in our patients were negative. Chest computerized tomography scan findings revealed a slightly and diffusely increased density of the pulmonary field, diffuse exfiltration or patchy shadows. Moreover, hemosiderin-laden macrophages were found in the sputum of five patients (cases 2, 5, 6, 9 and 10), in the gastric lavage fluid of two patients (cases 3 and 7) and in the bronchoalveolar lavage fluid of three patients (cases 1, 4 and 8).
All the patients received treatment with corticosteroid, leflunomide and MSCs. In addition, the patients received supportive therapy, including red blood cell transfusion (hemoglobin <70 g/l), oxygen inhalation treatment (oxygen saturation <95%) and antibiotic administration (bacterial infection) if necessary. Moreover, all the patients received vitamin D and calcium to prevent the side effects of the corticosteroid. Our results showed that this combination therapy was safe and well tolerated among patients and was not associated with the development of leukopenia and liver dysfunction. In addition, all the patients achieved a complete response. The median follow-up was 23 months (range: 4-34 months). Seven patients were off treatment at the end of the maintenance therapy. No patients relapsed during follow-up. All the patients remained well with no cough or hemoptysis. Laboratory tests showed normal hemoglobin and serum iron levels. Moreover, chest computerized tomography scan findings revealed no evidence of pulmonary hemorrhage, including the absence both of hemoptysis and of new pulmonary infiltrates.
Flow cytometry data regarding lymphocyte subpopulations before and after MSC administration are shown in Table 2 
D I S C U S S I O N
The clinical course of IPH is greatly variable, and diagnosis is usually delayed [13, 14] . Data from a large pediatric cohort have suggested that systematic screening for autoimmune diseases should be included in the diagnostic work-up [15] . In our experience, cough in combination with anemia should alert pediatricians to the possibility of IPH. In patients who have pneumonia with iron-deficiency anemia, a chest computerized tomography scan is warranted. Moreover, hemoptysis should be excluded from the secondary causes of pulmonary hemorrhage, including vasculitis, rheumatologic diseases, immune deficiency, glomerulonephritis and pulmonary tuberculosis. In our study, autoimmune antibodies were negative in all the patients. Last, but not least, the diagnosis of IPH can be confirmed by findings of hemosiderin-laden macrophages [16, 17] . In our patients, hemosiderin-laden macrophages were found in the sputum, gastric lavage fluid or bronchoalveolar lavage fluid of patients.
Owing to the rarity and variable clinical course of IPH, no randomized clinical trials have yet assessed the efficacy of different treatment modalities. The main treatments are corticosteroids administered according to various regimens. Corticosteroids have been associated with decreases in both pulmonary bleeding relapses and pulmonary fibrosis progression [18] . However, long-term maintenance therapy with corticosteroids may have no effect on the overall course or prognosis of IPH [19] . Moreover, this long-term treatment can be problematic because of well-known side effects that include growth retardation, cushingoid features, weight gain and development of cataracts. Other immunosuppressant agents, including azathioprine, hydroxychloroquine, cyclophosphamide, methotrexate and 6-mercaptopurine have been tried with variable results [20] [21] [22] .
In our study, all the patients were treated with corticosteroid, leflunomide and MSCs. Our results showed this therapeutic strategy was safe and effective. Side effects of the treatment were limited or absent for all the patients, and we did not find adverse effects such as fever, leucopenia, renal toxicity, liver dysfunction, peptic ulceration or growth retardation. All the patients achieved a complete response by follow-up. Leflunomide is an immunomodulatory drug that achieves its effects by inhibiting mitochondrial enzymes. Leflunomide has been used in the treatment of microscopic polyangiitis and rheumatoid arthritis [23, 24] . MSCs are a heterogeneous subset of stromal stem cells and can interact with cells of both the innate and the adaptive immune systems, leading to the modulation of several effector functions [25, 26] . On the basis of their immunoregulatory and tissue-protective properties, MSCs have been extensively investigated as a promising approach to treat many autoimmune diseases [27, 28] .
þ regulatory T cells was observed in two systemic lupus erythematosus patients after autologous MSC treatment [29] . Furthermore, MSCs were found to have the potential to directly or indirectly inhibit disease-associated Th17 cells [30] . Our results showed that MSC administration induced an increase in the percentage of CD4 þ CD25 þ regulatory T cells but a decrease in the percentage of Th17 cells among patients with IPH. However, MSC administration had no effect on the percentages of CD4 þ and CD8 þ cells. The precise mechanism of action of this combination therapy for pediatric IPH patients requires further investigation.
In conclusion, treatment with corticosteroid, leflunomide and MSCs for pediatric IPH patients was safe and effective. This combination therapy may have an effect on CD4 þ CD25 þ regulatory T cells and Th17 cells.
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